Skip to main content
Premium Trial:

Request an Annual Quote

Opko Partners with Bristol-Myers Squibb on Alzheimer's Blood Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Opko Health said today that it has entered into a collaboration agreement with Bristol-Myers Squibb to co-develop a blood test for Alzheimer's disease.

The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.

As reported by GWDN's sister publication ProteoMonitor, Opko is developing an Alzheimer's diagnostic using a new technique for detecting disease-specific antibodies developed by researchers at the Scripps Research Institute in Jupiter, Fla.

The technique developed at Scripps uses synthetic molecules called peptoids to screen for autoantibodies in blood associated with Alzheimer's disease, Thomas Kodadek, professor of chemistry and cancer biology at Scripps and a scientific director at Opko, told ProteoMonitor.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.